-
New Treatment Option Approved: Ilumya (tildrakizumab-asmn) for Psoriatic Arthritis
A New Milestone for Psoriatic Arthritis Care The U.S. Food and Drug Administration (FDA) has officially approved Ilumya (tildrakizumab-asmn) for the treatment of adults living with active psoriatic arthritis (PsA). This approval provides a significant new therapeutic option for patients managing this complex, inflammatory condition. Understanding Ilumya Ilumya is a humanized interleukin-23 (IL-23) p19 subunit…
-
A Major Milestone in Psoriatic Arthritis: FDA Approves Tremfya for Joint Damage Prevention
NYSE: $JNJ A Breakthrough for Psoriatic Arthritis Patients For those living with Psoriatic Arthritis (PsA), the goal of treatment has long been to manage pain and inflammation. However, a significant development from the FDA has raised the bar for what patients can expect from their therapy. The FDA has officially approved a label expansion for…